Diabetic Neuropathy Treatment Market Research Report - Global Forecast till 2030

Global Diabetic Neuropathy Treatment Market Research Report: By Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Treatment (Drugs, TENS, Others) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2030

ID: MRFR/HC/6887-HCR | August 2022 | Region: Global | 111 Pages         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER

6.1. Overview

6.2. Peripheral Neuropathy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Autonomic Neuropathy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Proximal Neuropathy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Focal Neuropathy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1. Analgesics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2. Antidepressant

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3. Anticonvulsants

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Transcutaneous Electrical Nerve Stimulation (TENS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Online Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Disorder Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. F. Hoffmann-La Roche Ltd

11.2.1. Company Overview

11.2.2. Disorder Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Eli Lilly and Company

11.3.1. Company Overview

11.3.2. Disorder Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Johnson & Johnson

11.4.1. Company Overview

11.4.2. Disorder Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline Plc

11.5.1. Company Overview

11.5.2. Disorder Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. LUPIN LIMITED

11.6.1. Company Overview

11.6.2. Disorder Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Glenmark Pharmaceuticals Limited

11.7.1. Company Overview

11.7.2. Disorder Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Depomed, Inc

11.8.1. Company Overview

11.8.2. Disorder Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Astellas Pharma Inc

11.9.1. Company Overview

11.9.2. Disorder Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Pfizer Inc

11.10.1. Company Overview

11.10.2. Disorder Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. MEDA Pharma GmBH & Co. KG

11.11.1. Company Overview

11.11.2. Disorder Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Others

12. APPENDIX

12.1. References

12.2. Related Reports 

LIST OF TABLES

TABLE 1 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 7 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 9 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 11 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 12 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 14 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 15 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 17 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 18 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 20 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 21 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 23 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 24 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 26 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 27 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 29 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 30 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET

FIGURE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY DISORDER, 2020 (%)

FIGURE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: DIABETIC NEUROPATHY TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 18 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 19 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 20 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 21 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 22 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 23 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 24 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 25 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 LUPIN LIMITED: KEY FINANCIALS

FIGURE 30 LUPIN LIMITED: SEGMENTAL REVENUE

FIGURE 31 LUPIN LIMITED: REGIONAL REVENUE

FIGURE 32 GLENMARK PHARMACEUTICALS LIMITED: KEY FINANCIALS

FIGURE 33 GLENMARK PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE

FIGURE 34 GLENMARK PHARMACEUTICALS LIMITED: REGIONAL REVENUE

FIGURE 35 DEPOMED, INC: KEY FINANCIALS

FIGURE 36 DEPOMED, INC: SEGMENTAL REVENUE

FIGURE 37 DEPOMED, INC: REGIONAL REVENUE

FIGURE 38 ASTELLAS PHARMA INC: KEY FINANCIALS

FIGURE 39 ASTELLAS PHARMA INC: SEGMENTAL REVENUE

FIGURE 40 ASTELLAS PHARMA INC: REGIONAL REVENUE

FIGURE 41 PFIZER INC: KEY FINANCIALS

FIGURE 42 PFIZER INC: SEGMENTAL REVENUE

FIGURE 43 PFIZER INC: REGIONAL REVENUE

FIGURE 44 MEDA PHARMA GMBH & CO. KG: KEY FINANCIALS

FIGURE 45 MEDA PHARMA GMBH & CO. KG: SEGMENTAL REVENUE

FIGURE 46 MEDA PHARMA GMBH & CO. KG: REGIONAL REVENUE

Diabetic Neuropathy Treatment Market

Diabetic Neuropathy Treatment Market is projected to grow at CAGR of 5.80% to reach USD 7,719.92 million by 2030.

Segmentation

By Disorder Peripheral Neuropathy Autonomic Neuropathy Proximal Neuropathy Focal Neuropathy
By Treatment Drugs Tens
By End-User Hospitals And Clinics Retail Pharmacy Online Pharmacy

Key Players

  • Abbott Laboratories (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Eli Lilly and Company (US)
  • Johnson & Johnson (US)
  • GlaxoSmithKline Plc (UK)
  • Lupin Limited (India)
  • Glenmark Pharmaceuticals Limited (India)
  • Depomed
  • Inc. (US)
  • Astellas Pharma Inc (Japan)Pfizer Inc (US)

Drivers

  • Growing global geriatric population
  • Rising awareness of advanced treatments for diabetic neuropathy.Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.
Speak to Analyst Request a Free Sample

Market Forecast


Global Diabetic Neuropathy Treatment Market is expected to cross USD 7,719.92 million by 2030 at a CAGR of 5.80%.


Market Synopsis


The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.


Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.


Market Influencer


The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.


Market Drivers



  • Growing global geriatric population.

  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.

  • Increasing research and development of new drugs to treat diabetic neuropathy disorder.

  • Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.

  • Rising awareness of advanced treatments for diabetic neuropathy.

  • Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.


Market Restraints



  • High treatment costs.

  • Availability of alternative therapies such as traditional medicine and physiotherapy.

  • Need for specialized equipment to diagnose and treat diabetic neuropathy.


Segmentation


By Disorder



  • Peripheral Neuropathy: The largest segment of the market, peripheral neuropathy afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.

  • Autonomic Neuropathy: This disorder generally afflicts elderly people. As of 2018, about 23 million people in the US had autonomic neuropathy and over a quarter of those afflicted could not perform daily activities.

  • Proximal Neuropathy: It is a rare type of nerve damage that occurs in hip, buttock, or thigh. It typically affects one side of the body and rarely spreads to the other side of the body. About 50% of patients suffering from diabetes have proximal neuropathy.

  • Focal Neuropathy: This focal neuropathy disorder afflicts roughly 3 out of every ten individuals who have diabetes with over 100 million people affected globally.


By Treatment



  • Drugs: The fastest-growing segment of the market, drugs are most widely used for the treatment of diabetic neuropathy. A rise in the number of FDA approvals for drugs to treat diabetic neuropathy is a key factor for the growth of the segment.

  • Transcutaneous Electrical Nerve Stimulation (TENS): The largest segment, TENS is the preferred treatment for many diabetic neuropathies as they reduce inflammation and suppress immune system activity.

  • Others: The other segment includes physiotherapy and electroacupuncture and various other treatment options for diabetic neuropathy.


By End-User



  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with diabetic neuropathy. Growing awareness and increasing efficiency of diabetic neuropathy treatment are projected to drive the growth of this segment during the forecast period.

  • Retail Pharmacy: A small segment. This center provides immediate pain relief and rudimentary drugs for diabetic neuropathy.

  • Online Pharmacy: Various drugs are used for the treatment of diabetic neuropathy which can be easily available in online pharmacy.

  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: The largest regional market. The prevalence of diabetic neuropathy is high in the Americas. The region also has a well-established healthcare industry. Out of the entire population, around 72.2% people in the US were suffering from diabetic neuropathy in 2017.



  • Europe: An increasing geriatric population is leading to a rise in the number of diabetic neuropathy disorder cases.



  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people afflicted with diabetic neuropathy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. Diabetic neuropathy is an increasing problem in Asia. Approximately 4000 patients were diagnosed with diabetic neuropathy in Korea in 2017, whereas in Japan, around 298 people were diagnosed with diabetic neuropathy in 2017.



  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.


Key Players



  • Abbott Laboratories (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Eli Lilly and Company (US)

  • Johnson & Johnson (US)

  • GlaxoSmithKline Plc (UK)

  • Lupin Limited (India)

  • Glenmark Pharmaceuticals Limited (India)

  • Depomed, Inc. (US)

  • Astellas Pharma Inc (Japan)

  • Pfizer Inc (US)

  • MEDA Pharma GmBH & Co. KG (Germany)

  • Others



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Diabetic neuropathy treatment market was valued at USD 7,719.92 million in 2030.

The global market is expected to exhibit a strong 5.80% CAGR over the forecast period from 2020 to 2030.

The growing prevalence of diabetes is the major driver for the market.

The Americas are the leading regional market for diabetic neuropathy treatment due to the growing prevalence of diabetes in the region.

Leading players in the market include Abbott, Astellas Pharma, and Pfizer, among others.